- Hormonal Intrauterine Device
- Copper Intrauterine Device
USA Intrauterine Contraceptive Devices Market was valued at USD 1,094.6 million in 2023 and is projected to reach USD 1,379.5 million by 2029. Favourable regulatory environment such as approval of IUDs for younger women who have never given birth and also FDA approval for extended use of IUDs is creating a strong impetus in the IUDs industry. In terms of sales revenue by method, the Hormonal Intrauterine Device segment accounted for more than 83% of revenue share and is projected to grow at 4.0% CAGR over the forecast period. The hormonal Intrauterine Device (IUD) is a highly effective contraceptive method that is becoming more widely available. It has therapeutic and non-contraceptive benefits, including lighter bleeding and pain alleviation, as well as fewer side effects than other hormonal treatments. Hormonal IUDs are one of the most effective forms of reversible contraception available. They have a failure rate of less than 1%, making them highly reliable in preventing unintended pregnancies.
The Hospitals segment accounted for 43.8% revenue share in the USA Intrauterine Contraceptive Devices Market, and the market is projected to grow at 4.3% CAGR over the forecast period.
Community Health Care Center segment accounted for 19.7% of revenue share in the USA Intrauterine Contraceptive Devices Market. Community health centers (CHCs) are an important source of care for many low-income and uninsured women of reproductive age. Over half of community health centers provide IUDs as part of the family planning services.
USA Intrauterine Devices Market Key Developments:
- On May 18, 2023, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced that its new next-generation, hormone-free, low-dose copper intrauterine device (IUD) showed positive results in a phase 3 study. In the trial, the Copper 175 mm2 IUD (VeraCept) was 99% effective in preventing pregnancy and well tolerated by the study participants.
- In June 2021, Sebela Pharmaceuticals Inc., in collaboration with PRA Health Sciences is conducting a phase III clinical trial to assess LevoCept, a long-acting reversible intrauterine system for contraceptive efficacy, safety and tolerability. The trial expected to complete in June 2027.
- In the United States, the VeraCept Intrauterine Contraceptive is now being tested in a clinical trial. (Its use is restricted to investigational purposes under US federal law). VeraCept is a low-dose copper-releasing intrauterine device that prevents pregnancy without the need of hormones. In the United States, VeraCept is conducting Phase 3 Clinical Trials.
- In March 2021, A clinical study was initiated to check the Impact of Contraceptives on Cervico-Vaginal Mucosa (UMPALA) in the United States. UMPALA is a research study aims to examine the impact of four approved contraceptives on cervical and vaginal tissues, as well as blood factors.
- In addition, In 2020, Bayer and Direct Relief teamed up to launch the "We're for Her" campaign. The primary goal of this effort was to ensure that women in deprived areas of the United States have access to effective contraception.
USA Intrauterine Devices Market Dynamics
Growing awareness about the IUD’s driving the market growth in the United States. Public health educators are using social marketing campaigns to raise knowledge of contraceptive options, such as generating video public service announcements and distributing them on social media. For example, Adolescents could be targeted by creating and distributing an educational video on fundamental IUD information. IUDs are also advised for all women by the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Paediatrics (AAP). Women's use of intrauterine devices has increased as a result of increasing awareness.
Furthermore, due to the lack of access to abortion and increased copayments, the repeal of the Affordable Care Act (ACA) in the United States has prompted a huge number of women to choose for long-acting reversible contraception (LARC), such as IUDs. This is bolstered by technological advancements like reusable and postpartum IUDs, which are expected to boost market development. On university and college campuses, various awareness initiatives about unwanted pregnancies are being held. As a result, demand for IUDs has increased in the United States.
Furthermore, because of the lower cost of these devices, IUDs are one of the most often used contraceptive methods in the United States. According to the Centers for Disease Control and Prevention’s 2017 – 2019 survey 65.3% of 15 – 49 years aged women using the contraception in USA and among these women, 10.4% are using the long-acting reversible contraceptives (LARCs). This number has steadily risen over the years and is projected to continue to rise in the future as more people become aware of the devices' benefits, which is expected to aid the segment's growth over the projection period.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
USA Intrauterine Devices Market Segmentation
By Method
By End User
- Hospitals
- Gynecology Clinics
- Community Health Centers
- Others
Frequently Asked Questions
The USA Intrauterine Contraceptive Devices Market was valued at USD 1,094.6 Million in 2023 and projected to grow at a CAGR of 3.9% over the forecast period.
The key market players operating in the United States Intrauterine Devices (IUD’s) Market are Abbvie Inc., Bayer AG, The Cooper Companies Inc.,, Viatris Inc., and Sebela Pharmaceuticals
The base year of the market study is 2023 and the forecast years are 2024-2030
- Abbvie Inc.,
- Bayer AG
- The Cooper Companies Inc.,
- Viatris Inc.,
- Sebela Pharmaceuticals